A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

NCT04871997 | Completed

• 1 other identifier: S1040
• Study Type: observational
• Target: 373
• Locations: 1 country
• Sites: 1

Brief Summary

A real-world study: Efficacy and safety of Anlotinib for advanced non-small cell lung cancer：This study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer in the real world, and to summarize the treatment experience of a broad population.

Conditions

NSCLC

Keywords

NSCLC; anlotinib; PFS

Outcome Measures

Primary Outcomes (1)

• progression-free survival (PFS)

  the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse

  2019.7-2022.7

Secondary Outcomes (3)

• overall survival (OS)

  2019.7-2022.7

• objective response rate (ORR)

  2019.7-2022.7

• disease control rate (DCR)

  2019.7-2022.7

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients diagnosed as advanced non-small cell lung cancer and treated with anlotinib were included，with no gender restriction

You may qualify if:

• Age: ≥18 years old, no gender limit.
• Diagnosed as advanced non-small cell lung cancer.
• At least one tumor lesion has not been subjected to local treatment such as irradiation in the past, and can be accurately measured, the longest diameter is ≥10 mm.
• Doctors evaluate the benefits of receiving Anlotinib treatment.
• The patient voluntarily joins the project and signs the informed consent. If any of the above items is "No", the patient is not suitable for this study.

You may not qualify if:

• Those who have been confirmed to be allergic to anlotinib and/or its excipients.
• Patients with anlotinib contraindications.

Sponsors & Collaborators

• Qian Chu: lead

Study Sites (1)

Hubei province

Wuhan, Hubei, 430030, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

All registered data are collected from real clinical practice cases.

Study Officials

• Qian Chu

  Tongji Hospital

  PRINCIPAL INVESTIGATOR

• Tienan Yi

  Xiangyang Central Hospital

  PRINCIPAL INVESTIGATOR

• Youhong Dong

  Xiangyang No.1 People's Hospital

  PRINCIPAL INVESTIGATOR

• Ruizhi Ran

  The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture

  PRINCIPAL INVESTIGATOR

• Yang Fu

  Xiangyang Hospital of Traditional Chinese Medicine

  PRINCIPAL INVESTIGATOR

• Guangqiao Qu

  The Central Hospital of Xiao Gan

  PRINCIPAL INVESTIGATOR

• Jun Li

  The Central Hospital of Xiao Gan

  PRINCIPAL INVESTIGATOR

• Yinping Li

  The Central Hospital of Xiao Gan

  PRINCIPAL INVESTIGATOR

• Yanhua Xu

  Jingzhou Central Hospital

  PRINCIPAL INVESTIGATOR

• Xinhua Xu

  Yichang Central People's Hospital

  PRINCIPAL INVESTIGATOR

• Zhiguo Luo

  Affiliated Taihe Hospital of Hubei University of Medicine

  PRINCIPAL INVESTIGATOR

• Fengjun Cao

  Shiyan Renmin Hospital

  PRINCIPAL INVESTIGATOR

• Li Kuang

  Dongfeng Hospital Affiliated to Hubei Medical College

  PRINCIPAL INVESTIGATOR

• Yifa Yin

  Yichang Second People's Hospital

  PRINCIPAL INVESTIGATOR

• Guiming Chen

  JingMen NO.2 People's Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 26, 2021
• First Posted: May 4, 2021
• Study Start: July 12, 2019
• Primary Completion: July 16, 2022
• Study Completion: July 16, 2022
• Last Updated: October 21, 2022

Record last verified: 2022-10

Locations

CN (1)